Member Info for rivaldo

Terrific stuff, with two big forward sales for £66m: Https://www.investegate.co.uk/watkin-jones-plc--wjg-/rns/completion-of-forward-sales-of-two-developments/201710030700034787S/ So impressive that all forward sales for 2017, 2018 and already almost 75% of 2019's have now been delivered. The markets just love such forward visibility. Beautiful.

Time for the bounce.....hugely undervalued imo, and simply falling on low volumes at a quiet time, with the MMs taking full advantage.

Finncap reiterate their 586p target and Buy recommendation following today's update. They state that "Renew�s strong track record of delivering essential services on large, long-term frameworks can command a higher rating (currently 12.8x FY 2017E EPS)."

The article below is from yesterday's Sunday Times - Ginsters could buy VLE's Shire Foods in a heartbeat given their size. Worth noting that West Cornwall Pasty Co, which cost Ginsters �13m,had in the year to March'16 �13m revenues, EBITDA of �1.02m, operating profit of �560k and post tax profit of �380k. Shire Foods in the same year had �15.2m revenues and �1.15m PBT - both much higher than the West Cornwall Past Co. Plus Shire Foods has �2m+ of freehold property (plus substantial other equipment). In our NAV calculations, we've been attributing only around �6m or so to Shire including the freehold property. But you could at least double that to �12m and possibly �15m on the above basis - which would add another 150p-200p+ to the potential NAV. Https://www.thetimes.co.uk/edition/business/medical-app-babylons-burning-cash-ztzb9vbxt "Big appetite for Ginsters Sales at Samworth Brothers, owner of Ginsters Cornish pasties, jumped 5.6% last year to �951.9m. The Leicestershire-based food manufacturer, which produces more than 1.5m sandwiches a week and owns a string of outlets, reported profits of �45.8m for the year to December 31, according to accounts lodged at Companies House. The group, founded in 1896, snapped up West Cornwall Pasty Company for �13m last December. It now employs almost 8,400 people, and is the largest distributor of Melton Mowbray pork pies."

Great news - a follow-on contract for �1.65m and likely more to come. Must be one happy customer!

Lovely jubbly - trading nicely in line with expectations for the year, and now sitting on cash ready for further acquisitions: Https://www.investegate.co.uk/renew-holdings-plc--rnwh-/rns/trading-update-and-notice-of-results/201710020700063036S/ Increased margins too, alongside the increases in revenues and profit.

with a VENN operations manager re their clinical trial expertise: Https://www.med-technews.com/features/tried-and-tested-venn-life-sciences-clinical-trials/ Extracts: "Q&A: talking investigator initiated trials with Venn Life Sciences by Dave Gray 28 September 2017 Behind every great medical device, there�s a great clinical trial. MTI editor Dave Gray spoke to Colette Donaghy, clinical operations manager, Venn Life Sciences, to find out what goes into making a device trial successful." "....Donaghy says that Venn continues to attract innovators from around the globe. In fact, the group recently collaborated in a clinical trial in cardiology which turned out to be one of the largest investigator-lead studies in disease of the left main artery being conducted anywhere in the world. The project began when Venn�s COO was approached by one of two lead investigators, Professor Robert-jan van Geuns at the Erasmus University in the Netherlands. Both he and Professor Keith Oldroyd who is based in the Golden Jubilee Hospital in Glasgow realised at a very early stage that they needed help to conduct this large-scale investigator initiated study.... .....The first challenge was the administrative task of setting up the study in different countries. To do that requires knowledge of the regulatory pathways in each country. Venn has experts around the world capable of undertaking this kind of work. Donaghy says that this specialist knowledge is invaluable when trying to conduct trials on an international scale. �In each country we had to go through the relevant ethical review bodies, who looked at the study, checked that they were happy for it to be conducted, and that there would be no negative impact for the patient.� The other challenge for the client was setting up contracts. Venn needed to set up a contract with each institution, and in some cases with each investigator..... �There�s a lot to do when setting up an international clinical trial. Each country needs to be set up individually and the sites trained in the study processes. And if that�s going to be happening in different countries, then you need people who can speak the language.� Venn has sites in Russia, Poland, Germany, France, the Netherlands and the UK. The trial is ongoing, and Donaghy says that there is significant interest from clinicians in the eventual findings and the primary outcomes at 24 months. �This study will be followed up for the next five years. We will monitor major adverse coronary events and they�ll be classed into categories � e.g. bleeding, thrombosis, stent replacement, etc. We will monitor this over a period of five years, allowing us to look back and see why those things happened. �Currently the client is highly satisfied that we delivered the trial within the timelines that we were given, and that we managed to get full re

More detail on that ACSO upgrade - incidentally it's increased to 2151p, NOT the 2115p per the article: http ://www.proactiveinvestors.co.uk/companies/news/184828/city-broker-thinks-accesso-shares-are-now-worth-more-than-21-after-last-weeks-solid-interims-184828.html "City broker thinks Accesso shares are now worth more than �21 after last week�s �solid� interims 10:19 29 Sep 2017 �The major driver to our target price increasing from �17.47 to �21.15 is the roll-forward of our base valuation year to reflect a full-year contribution from the Ingresso and TE2 acquisitions� Analysts at N+1 Singer have upgraded their recommendation and hiked their price target for ticket and queue management firm Accesso Technology Group PLC (LON:ACSO) following last week�s �solid� set of interims. Accesso signed up 40 new clients in the first half which helped it deliver an adjusted operating profit � which is what it considers to be a key underlying metric � of US$46.6mln (H1 2016: US$39.7mln). N+1�s Adam Lawson has upped his full-year earnings per share forecast to reflect a lower effective tax rate but said the main reason for his bullish outlook is because of the impact of recent acquisitions. �The major driver to our target price increasing from �17.47 to �21.15 is the roll-forward of our base valuation year to reflect a full-year contribution from the Ingresso and TE2 acquisitions,� Lawson wrote in a note this morning. This increase, together with improving earnings momentum, drives our upgrade from �hold� to �buy�.�

Amati VCT 2 published their interims last week, and had this to say about KWS: Https://www.investegate.co.uk/amati-vct-2-plc--at2-/rns/half-year-report/201709281705511556S/ "The greatest contributor to performance over the six months under review was Keywords Studios ("Keywords"), the technical services provider to the video games industry, its shares rising 109%. Keywords continued its acquisition strategy, acquiring five businesses, which all fit the template of expanding the group's geographical coverage and service lines. The most eye-catching of these recent acquisitions were a software development business and a video games content management software provider, both giving Keywords entirely new services to offer their customer base. Keywords finds itself in an enviable position: its market remains highly fragmented yet customers wish to deal with fewer vendors. By continuing to consolidate its industry, it can present itself to video games publishers as a one-stop solution for all video games support services. The market for outsourced video games services continues to demonstrate healthy levels of growth which, when combined with earnings enhancing acquisitions, provide a powerful catalyst for shareholder returns."

Useful background on the Overseas Internet Casino deal: Https://calvinayre.com/2017/09/28/business/gan-real-money-gambling-us-casino-operator/ Extract: "GAN also shed a little more light on the "Overseas Internet Casino" deal it inked with an unidentified "major US casino operator" in September 2016. While the operator's identity remains a state secret, GAN now says the overseas site will launch in Q4 2017. GAN previously hinted that its mystery client was already a customer, and a "major multi-property casino operator in a regional US gaming market" with $1b in annual revenue. For the record, the companies on GAN's client roster that fit that description include Station Casinos, JACK Entertainment, Isle of Capri and Oklahoma's Chickasaw Nation. GAN CEO Dermot Smurfit claimed GAN will benefit from the unnamed casino operator's "material marketing investment". Since H1 ended, GAN says it has received �2.2m in cash payments related to the launch of this online casino and a "2016 claim to ongoing research and development activity."

Encouraging to see a subsidiary director buying �25,000 of shares at 188p: Https://www.investegate.co.uk/premier-technical--ptsg-/rns/pdmr-shareholding/201709290700101585S/

Agreed Abercorn. Excellent trading statement on Friday - lovely and confident. I bought in recently, just before the statement. Finncap, Peel Hunt, Shore Capital and N+1 Singer all reiterated their Buys after the statement. Finncap have a 400p target, and Singer and Peel Hunt both have a 388p target.

Panmure Gordon on Friday initiated coverage of XAR with a Buy and a 556p target - and this assumes no contribution at all from the 3-D printing HSS technology, which is a "significant potential source of upside risk".

N+1 Singer upgraded on Friday to Buy (from Hold) and have increased their target price to 2151p (from 1747p)....

A 100,000 buy at 12.41p has caused a tick up. I note this morning's acquisition by Ergomed of PSR, "an international niche contract research organisation". They're paying �5.7m for a business with �4.7m of annual revenues and �0.34m EBITDA. VENN are forecast to make �18.5m revenues this year, with �0.9m EBITDA. On a PSR basis, this would value VENN at around �22.5m. On an EBITDA basis this would value VENN at around �15m. This compares to VENN's current m/cap of �8.6m.

Https://www.printweek.com/print-week/news/1162362/communisis-investor-ups-stake Communisis investor ups stake A high-profile investor has quietly increased his stake in Communisis to more than 22%. Richard Griffiths is a former sheep farmer and rugby player who found fame and fortune in the City after founding finance house Evolution Group PLC. He went on to found Ora Capital Partners, and currently controls a number of funds. Over the summer Griffiths upped his stake in Communisis, via seven separate investment vehicles, to 47,443,061 shares, or 22.66% of the group. Communisis chief executive Andy Blundell told PrintWeek that the group�s board had a good relationship with Griffiths. �Richard has been a shareholder for years and we know him very well. He controls his own funds and has recently topped up his holding,� Blundell said. �He�s supportive of the business, knows us and our strategy well, and we�re glad to have him on board.� A representative of Griffiths declined to comment, and said: �We don�t generally provide comment on our investment motivations.� Other major Communisis shareholders at the group�s last financial year-end included Henderson Group (9.99% stake) and Majedie Asset Management (5.13%). Shares in Communisis hit a 52-week high of 61p earlier this month. The �361.9m turnover group currently has a market capitalisation of �124m, higher than that of St Ives, at �100m. Communisis confirmed that it had won the HSBC marcomms contract previously handled by St Ives alongside its interim results in August.

Liberum say Buy today with a 64p target price. They conclude: "Forecasts and valuation Our forecasts now show revenue growth of 25% (was 22%) driven by simulated gaming and real-money in the US and Italy. We have increased our FY17e Group EBITDA forecast from �0.3m to �0.5m reflecting a number of H2 opportunities (next year we increase our EBITDA projection from �2.0m to �2.3m). Within Simulated 5 Casinos went live in H1 and will make a full contribution in H2. The investment in headcount in Bulgaria and Israel highlight the Management's focus on scaling the business but effectively controlling costs. The business is highly operationally geared to new customer wins and increasing player days and ARPU from existing partnerships. Although GAN is demonstrating considerable momentum in simulated gaming in the US, its casino clients launched so far only represent c.1% of the addressable market. Meanwhile, the upside from regulation of internet casino gaming in more states in the US still offers the possibility of longer-term returns. We factor in the various revenue streams and their potential into a sum-of-the-parts analysis, which highlights significant short-term upside towards our unchanged target price of 64p per share."

Davy Stockbrokers are nicely positive this morning - the core business is doing well enough as it is, but any positive news from Pennsylvania or elsewhere would send the share price into orbit: "GAN EBITDA break-even in H1 with revenue growth likely to accelerate in H2 David Jennings | Morning briefing | GAN�s H1 performance was slightly better than expected at the EBITDA line and in line at the net income line. The group continues to grow its sustainable revenue base while maintaining good cost discipline. Further growth in simulated revenues looks likely in H2, while the market will continue to monitor the prospects for real money gaming regulation in Pennsylvania and elsewhere. Given the foundations that the group is putting in place in the US, it would no doubt benefit materially should such regulation be forthcoming. Even in the absence of such change, the simulated offering seems to be building traction."

Beaufort Securities today retain their 23p target. They forecast 1.77p EPS this year and 2.42p EPS next year - those are P/E's of 6.9 falling to just 5.1..... "Our View: Impressive stuff! The first half of 2017 saw DekelOil acquire 100% of Ayenouan, further strengthen its balance sheet, pay out a maiden dividend and report record sales and profits. There is clear momentum behind the business, both at the operational and corporate level and Beaufort expects this to be maintained going forward. Having proven its business plan, management is now keen to roll-out its vertically integrated model, which includes a state of the art nursery, mill, and company-owned estates, elsewhere in the region. At Guitry, operations have already formally commenced and the Board remains in discussions to acquire an interest in Norpalm Ghana Limited ('NGL'), a vertically integrated palm oil producer in Western Ghana which has approximately 4,000 hectares of mature palm plantations under ownership and produces some 15,000 tonnes of CPO a year from a 30t/hr mill. In addition to the revenue it generates from selling this produce into the domestic Ghanaian market, NGL also operates a palm kernel oil press which produces approximately 2,000 tn of PKO. There can be no guarantee current discussions will result in DekelOil acquiring NGL, but they nevertheless demonstrate management's confidence in its ability to replicate success already achieved. Having proven both the operating model and ability to implement it, shareholders should be reasonably confident of further progress as DekelOil seeks to transform itself into a leading West African palm oil producer. Indeed, Beaufort considers DekelOil is capable of producing as much as �2.7m free cashflow during 2017E, followed by around �6m the year after. Importantly also, yesterday's update demonstrates management willingness to move its ambitious planning forward without exposing shareholders to a higher risk profile. Based on 2017E and 2018E revenues estimates of �33.1m and �36.8m, delivering fully-diluted earnings 1.77p and 2.42p respectively, the shares trade on forward multiples of just 6.9x and 5.1x respectively while offering yields of 1.6% and 1.8%. Beaufort retains its Buy recommendation on DekelOil, while repeating its price target of 23p/share."

Good news all round - much improved: https://www.investegate.co.uk/gan-plc--gan-/rns/half-year-report/201709280700060334S/ Excellent numbers, with a maiden clean EBITDA, 86% recurring revenues, lots of new contracts now about to produce income, �3.3m cash, the Overseas Internet Casino launching in Q4 for a US casino....and a VERY positive outlook: "The Group generated positive clean EBITDA1 in H1 2017 following a substantial multi-year period of investment focused on the US land-based casino Industry. We anticipate this favourable EBITDA trend to continue throughout H2 2017. The first half of 2017 saw continued growth in recurring revenues driven by the launch of five new clients of Simulated Gaming and strong growth in real money Regulated Gaming markets in the US and Europe. We remain encouraged by the growth characteristics of Simulated Gaming and have already seen a major uplift in player activity as we begin to experience the onset of the seasonally strong Autumn/Fall period. GAN's Overseas Internet Casino for one of the largest casino operating groups in the US represents the culmination of GAN's long-term mission to move land-based US casinos online in domestic US intra-State markets or selected International regulated markets. This represents an exciting new B2B business for GAN, which will benefit greatly from the client's material marketing investment. As the numbers illustrate our Group has now moved into sustainable profitability at the clean EBITDA1 level. Growth prospects for Simulated Gaming� and real money Regulated Gaming continue to offer the Company a viable path to creating significant incremental shareholder value."